Report - 2010
Introduction

**Grant Programmes 2010:**

**EFSD**
Clinical Research Grants in the Field of Diabetes  
6

**EFSD**
New Horizons Collaborative Research Initiative  
7

**EFSD**
Research Programme in Diabetes and Cancer  
8

**EFSD/Amylin**
Paul Langerhans Grants on Interaction between the Brain, Gut, Liver and Periphery and its Importance in Diabetes  
9

**EFSD/Chinese Diabetes Society/Lilly**
Collaborative Diabetes Research Programme  
10

**EFSD/D-Cure**
Young Investigator Awards for Collaborative Diabetes Research between Israel and Europe  
11

**EFSD/GlaxoSmithKline**
Programme in Immunomodulation and/or Modulation of the Incretin Pathway in Type 1 and Type 2 Diabetes  
12

**EFSD/JDRF/Novo Nordisk**
European Programme in Type 1 Diabetes Research  
13

**EFSD/Lilly**
European Diabetes Research Programme  
15

**EFSD/Merck Sharp & Dohme (MSD)**
European Basic Research Programme on Beta Cell Function and Survival  
16

**EFSD/Merck Sharp & Dohme (MSD)**
European Clinical Research Programme on Incretins, Gut Physiology and Pancreatic Islets in Type 2 Diabetes  
17

**EFSD/Novo Nordisk**
Partnership for Diabetes Research in Europe  
18

**EFSD/Pfizer**
European Programme for Research into Cardiovascular Risk Reduction in Patients with Diabetes  
19
EFSD/sanofi-aventis
European Research Programme in Micro- and Macrovascular Complications Of Diabetes 20

Fellowships 2010:

EFSD Albert Renold
Travel Fellowships supported by Merck Sharp & Dohme (MSD) 22

EFSD/Chinese Diabetes Society/Lilly
Research Fellowships 23

EFSD/Lilly
Research Fellowships 24

New Programmes 2011:

EFSD
European Diabetes Research Programme in Patient Education supported by an educational research grant from AstraZeneca/BMS 26

EFSD/Janssen
Programme for the Study of the Role of the Kidney in Diabetes 27

EFSD/MSD
Fellowships for Research on the Endocrine Pancreas 28

Note: the above relates solely to programmes which have been officially agreed at the time of writing this Report.

____________________________________________________________________

EFSD Review Committee Members 29

EFSD Executive Committee and Administration 30
In 1999 the European Association for the Study of Diabetes (EASD) created its own Foundation - the European Foundation for the Study of Diabetes (EFSD) - in order to support more actively diabetes research in Europe and to serve even more effectively the goals of EASD, which are: to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge, and to facilitate its application.

EFSD is a non-profit foundation, which seeks to support the highest quality research in Europe to find a cure for all types of diabetes and associated complications and to prevent their onset. EFSD aims to co-operate with other government and non-government agencies in order to increase funding in European diabetes research as a means of achieving its goals. Through its various activities and programmes, the Foundation also strives to enhance awareness in Europe of the severity and magnitude of this devastating disease. It is the ambition of the Executive Committee to develop EFSD as the main European funding agency for diabetes research.

The Foundation is closely related to EASD; it is governed exclusively by the Executive Committee of EASD, which itself is under the close supervision of the EASD Council and General Assembly. The Foundation operates on a strictly non-profit basis under the control of the relevant authorities in Germany.

EFSD and its partners bring over Euro 74 Million to European diabetes research

In order to foster diabetes research at the highest level in Europe, EFSD has entered into innovative partnerships with other foundations and with industry. Through such partnerships, as well as its own stand-alone funding initiatives, to date EFSD has committed over Euro 74 Million to diabetes research in Europe.

Further information on EFSD Award Programmes is available on the website of the Foundation: www.EuropeanDiabetesFoundation.org. An RFA (request for applications) for each Programme is printed in Diabetologia (the official journal of EASD), and announced in the monthly e-mail sent to EASD members.

All applications are subject to rigorous peer review by a fully independent panel of leading experts in the field, and awards are based on scientific merit. Applications from non-profit organisations are welcome from Europe or any associated country as well as named non-European countries in the context of collaborative research programmes.
GRANT

PROGRAMMES

2010
Clinical Research Grants in the Field of Diabetes

Plan

The EFSD Clinical Research Grants Programme was created to stimulate research into all aspects of diabetes, but with particular reference to epidemiology/genetics of prediabetes, diabetes and its micro- and macrovascular complications, pathophysiology and clinical aspects including vascular physiology and obesity. The proposed investigation must be carried out in humans; although in vitro and ex vivo studies are acceptable, the in vivo component must clearly be the more relevant part of the project.

Funding Commitment and Instruments

Starting in 2007, this stand-alone EFSD Programme has committed a total of Euro 3.8 million towards clinical research in diabetes, with awards of up to Euro 300,000 over a period of up to three years.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Angelo Avogaro: University of Padova - Italy
Ellen Blaak: Maastricht University - The Netherlands
Rainer Böger: University Medical Centre Hamburg-Eppendorf - Germany
Carmine Fanelli: University of Perugia - Italy
Bettina Nowotny: German Diabetes Center - Düsseldorf, Germany
Allan Vaag: Rigshospitalet – Copenhagen University, Denmark
New Horizons Collaborative Research Initiative

Plan

There is a rich history of diabetes research throughout Europe and its associated states. Historically, however, funding for such research tends to be unevenly distributed. The Foundation now seeks to redress in part this imbalance and to foster inter-regional collaboration in diabetes research throughout Europe by making available grants through the EFSD New Horizons Collaborative Research Initiative.

This Programme therefore aims to foster inter-regional collaboration in diabetes research throughout Europe on a competitive basis. It is open to investigators working in institutions in the following countries and proposing to collaborate with an investigator from a European country not on this list: Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Hungary, Latvia, Lithuania, FYRo Macedonia, Moldavia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, and Ukraine.

Funding Commitment and Instruments

Up to Euro 2.1 million has been made available for the period 2009 - 2011 to fund basic and clinical research grants of up to Euro 100,000 and Euro 300,000 respectively.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

- Maija Dambrova: Latvian Institute of Organic Synthesis – Latvia collaborating with Rainer Breitling: University of Glasgow - UK
- Jan Kopecky: Institute of Physiology - Czech Republic collaborating with Jaap Keijer: Wageningen University - The Netherlands
- Koba Kupreishvili: Georgian National Insitute of Medical Research - Georgia collaborating with Hans Niessen: Free University Medical Centre - The Netherlands
- Adrian Manea: Instutite 'Nicolae Simionescu' - Romania collaborating with Shlomo Sasson: Hebrew University of Jerusalem - Israel
- Mirjana Pibernik-Okanovic: Vuk Vrhovac University Clinic - Croatia collaborating with Norbert Hermanns: Diabetes Research Institute - Germany
- Raivo Ulbo: University of Tartu - Estonia collaborating with Bart Roep: Leiden University Medical Center - The Netherlands
- Jozef Ukropec: Slovak Academy of Sciences - Slovakia collaborating with Christian Wolfrum: Institute of Molecular Systems Biology - Switzerland
Plan

The EFSD Research Programme in Diabetes and Cancer was established in order to stimulate and accelerate European research aimed at investigating why diabetes is associated with increased morbidity and mortality in certain forms of cancer. The role of diabetes therapy including molecular mechanisms is also of interest, and applications for projects carried out in collaboration between diabetes and cancer research institutions are especially welcome.

Funding Commitment and Instruments

Euro 3.7 million has been made available over the next three years for research in the framework of the Programme. Research is supported through the award of grants of up to Euro 100,000 for basic research projects and Euro 400,000 for clinical research projects.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Frédéric Bost: Nice University Hospital - France
Bendix Carstensen: Copenhagen University - Denmark
Craig Currie: Cardiff University - UK collaborating with
Edwin Gale: Bristol University – UK
Michelangelo Foti: University of Geneva - Switzerland
Andreas Geier: University Hospital Zurich - Switzerland collaborating with
Oliver Tschopp: University Hospital Zurich - Switzerland
Birgit Gustafson: Sahlgrenska University Hospital - Gothenburg, Sweden collaborating with
Sahlgrenska University Hospital - Gothenburg, Sweden: Margit Mahlapuu
Claire Perks: Southmead Hospital - Bristol, UK
Andrew Renehan: University of Manchester - UK collaborating with
Iain Buchan: University of Manchester - UK
Guadalupe Sabio Buzo: National Centre for Biotechnology - Madrid, Spain collaborating with
Miguel Marcos Martin: University Hospital Salamanca - Spain
Giovanni Solinas: University of Fribourg - Switzerland collaborating with
Matthias Wymann: University of Basel – Switzerland
Lonneke van de Poll-Franse: Eindhoven & Tilburg University - The Netherlands collaborating with Francois Pouwer: Tilburg University - The Netherlands
Paul Langerhans Grants on Interaction between the Brain, Gut, Liver and Periphery and its Importance in Diabetes

**Background**

Amylin Pharmaceuticals Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialisation of innovative medicines. The company was founded in 1987 and since then has built a strong foundation on research and development.

**Plan**

EFSD and Amylin established a partnership in 2005 to provide grants for studies on the integrated physiology of the entero-insular axis and the brain in metabolic homeostasis, and particularly the following: physiology of release and action of gut hormones including the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP); islet hormones including amylin and glucagon; localisation and expression of GLP-1, GIP, amylin and glucagon receptors and their regulation, impact of hyperglycaemia on expression, release and action of gastrointestinal and pancreatic hormones; cross-talk between gut, brain and islet signals; neural regulation of the gut and islet and the role of central neurohormonal signalling in diabetes and obesity; changes in entero-insular interaction induced by bariatric surgery and neurohormonal regulation of weight loss, including gut, pancreatic and adipocyte-derived hormones.

In 2010, the Programme offered grants up to Euro 100,000 for basic research and Euro 300,000 for clinical research.

**Funding Commitments and Instruments**

Since its creation in 2005, and with additional funds up to and including 2010, the total funding commitment of the Partnership has reached **Euro 1.6 million**.

**Awards in 2010**

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

- Francesca Frigerio: University of Milan - Italy
- Viola Nordström: German Cancer Research Center - Heidelberg, Germany
- Thomas Solomon: Copenhagen University - Denmark
Programme for Collaborative Diabetes Research between China and Europe

Background

Founded in 1991, the Chinese Diabetes Society conducts public education programmes, epidemiological surveys and research in China. The mission of CDS is to prevent and treat diabetes and provide information to help educate people living with diabetes, their families, health care professionals, and the public about this disease.

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Lilly is in Indianapolis, Indiana, USA.

Plan

This partnership targets collaborative research endeavours between European and Chinese research centres and/or individual investigators in the area of diabetes and its complications.

Funding Commitment and Instruments

Total funding of **Euro 1.2 million** has been committed from 2008 – 2010. Two basic science research grants in the sum of up to Euro 100,000 and one clinical outcomes research grant in the sum of up to Euro 200,000 will be made available annually, for research to be carried out in China in collaboration with a European research institution.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Haibing Chen: Shanghai Jiaotong University **collaborating with**
Rudolf William Bilous: Newcastle University - UK
Yong Tao: Peking University **collaborating with**
Hans-Peter Hammes: University of Heidelberg - Germany
Young Investigator Awards for Collaborative Diabetes Research between Israel and Europe

Background

D-Cure Diabetes Care in Israel R.A. (D-Cure) is a recently established non-profit organisation that aims to advance basic and clinical research into diabetes in Israel. This EFSD/D-Cure Programme is further supported by a charitable donation from another Israeli Foundation and the Berlin Charitable Trust.

Plan

This partnership programme encourages new projects aimed at advancing current knowledge in type 2 diabetes which are undertaken by young investigators working in Israel, in collaboration with an investigator working in another country in Europe.

Funding Commitment and Instruments

Starting in 2009, the partnership has committed a total of US$ 350,000 for research grants up to US$ 75,000 each.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Arie Lev Gruzman: Bar Ilan University collaborating with
Jürgen Eckel: German Diabetes Center – Düsseldorf, Germany
Eran Hornstein: Weizmann Institute of Science collaborating with
Harry Heimberg: Free University Brussels - Belgium
Rotem Karni: The Hebrew University of Jerusalem collaborating with
Per-Olof Berggren: Karolinska Institute – Stockholm, Sweden
Programme in Immunomodulation and/or Modulation of the Incretin Pathway in Type 1 and Type 2 Diabetes

Background

Headquartered in the UK, and with operations based in the US, GlaxoSmithKline is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. Its mission is to improve the quality of human life by enabling people to do more, feel better and live longer.

Plan

The EFSD/GlaxoSmithKline Grant Programme seeks to promote research that will broaden our understanding of the impact of modulating the immune system in autoimmune type 1 diabetes as well as in inflammation of type 2 diabetes. It also seeks to accelerate research into the role of the incretin pathway in diabetes and its complications and possible interaction or common mechanisms between this pathway and the immune system.

Funding Commitment and Instruments

Established in 2007 and since renewed annually, the total commitment of this partnership to date is **Euro 1.9 million**, made available as grants each of up to Euro 100,000 with special requests for amounts of up to Euro 300,000 in total being considered.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Núria Alonso Pedrol: Hospital Germans Trias - Barcelona, Spain
Victor Gault: University of Ulster - UK
Rosa Simões Fernandes: IBILI - Coimbra, Portugal
Sophie Van Linthout: Charité University Hospital - Berlin, Germany
Sergei Zaitsev : Karolinska Institute - Stockholm, Sweden
European Programme in Type 1 Diabetes Research

Background

The mission of the Juvenile Diabetes Research Foundation International (JDRF) is to find a cure for diabetes and its complications through the support of research. JDRF was founded in 1970 by parents of children with diabetes who were convinced that the disease could be cured. JDRF gives more money to diabetes research than any other non-profit, non-governmental health agency in the world.

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Novo Nordisk has companies and information offices in more than 60 countries.

Plan

The EFSD/JDRF/Novo Nordisk Programme in Type 1 Diabetes Research aims to foster multi-disciplinary research targeted at finding a cure for type 1 diabetes and its complications. The specific goals of the Programme are: to promote the highest quality of basic and clinical biomedical research in Europe and its associated countries applicable to type 1 diabetes, to expedite the practical application of scientific advances in our understanding of the aetiology, pathogenesis, treatment and prevention of type 1 diabetes and its complications, to encourage clinical translational research bridging the bench and the bedside, and to increase awareness of type 1 diabetes research throughout Europe.

Funding Commitment and Instruments

The EFSD/JDRF/Novo Nordisk European Programme in Type 1 Diabetes Research was established in 2001 and has to date made a total combined commitment of Euro 11.75 million.
Grants of up to Euro 100,000 each were available with special requests for amounts of up to Euro 400,000 in total being considered.

**Awards in 2010**

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Isabella Artner: Lund University - Sweden  
Christian Boitard: Hospital Cochin - Paris, France  
Decio L. Eizirik: Free University Brussels - Belgium  
Marika Falcone: San Raffaele Scientific Institute - Milan, Italy  
Thomas Mandrup-Poulsen: Copenhagen University – Denmark  
Rory McCrimmon: Dundee University – UK  
Olli Simell: District Hospital of Southwest Finland - Turku, Finland
European Diabetes Research Programme

Background

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Lilly is in Indianapolis, Indiana, USA.

Plan

The EFSD/Lilly European Diabetes Research Programme is established within the frame of the EFSD/Lilly Fund. The goals of the Fund are: to promote increased European research in diabetes, support training and mobility programmes in diabetes research for young clinicians and scientists, and increase awareness of the burden of diabetes and its complications throughout Europe. Launched in 2003, the Fund has now reached a total commitment of **Euro 9.3 million** to fund its various activities, including research grant and fellowship programmes.

Funding Commitment and Instruments

To date, the EFSD/Lilly Fund has contributed **Euro 4.550 million** towards the EFSD/Lilly Diabetes Research Programme, in the form of grants of up to Euro 100,000 each.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

- Anna Akhmanova: Erasmus Medical Centre - Rotterdam, The Netherlands
- Philippe Froguel: Pasteur Institute of Lille - France
- Stephan Herzig: German Cancer Research Center - Heidelberg, Germany
- Richard Ijzerman: Free University Medical Center - The Netherlands
- Sander Kersten: Wageningen University - The Netherlands
- Margit Mahlapuu: Gothenburg University - Sweden
- Suzanne Mandrup: University of Southern Denmark - Odense, Denmark
- Hindrik Mulder: Lund University - Malmö, Sweden
- José Ribeiro Bessa: University Pablo de Olavide - Seville, Spain
- Roy Taylor: Newcastle University - UK
- Emmanuel Van Obberghen: University of Nice – France
European Basic Research Programme on Beta Cell Function and Survival

Background

Merck & Co, Inc is a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck Sharp & Dohme, or MSD, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

Plan

These Programme awards are intended to stimulate and accelerate European research into all aspects of beta cell function and survival, with particular emphasis on the following: increasing beta cell mass/function, mechanisms of glucose-stimulated insulin secretion, mechanisms of beta cell dysfunction, including beta cell gluco- and lipotoxicity, non-invasive imaging of beta cells, and beta cell intermediary metabolism.

Funding Commitment and Instruments

This partnership Programme was established in 2005 and renewed in 2007 for a total commitment of Euro 3.2 million, to be distributed in the form of grants, each of up to Euro 100,000.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Nils Billestrup: University of Copenhagen - Denmark
Charna Dibner: University Hospital of Geneva - Switzerland
Jochen Lang: Bordeaux University - Pessac, France
Stephan Schneider: Ruhr-University Bochum - Germany
Anders Tengholm: Uppsala University - Sweden
Bernard Thorens: Lausanne University - Switzerland
Mireille Vasseur-Cognet: Paris Descartes University - France
European Clinical Research Programme on Incretins, Gut Physiology and Pancreatic Islets in Type 2 Diabetes

Background

Merck & Co, Inc is a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck Sharp & Dohme, or MSD, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

Plan

These Programme awards are intended to stimulate and accelerate European research into clinical aspects of type 2 diabetes mellitus, focusing on the following: incretin physiology, DPP-4 inhibition, gut physiology as it relates to metabolic control, and islet cell function and survival. Areas of particular interest include alterations in islet cell mass/function in diabetes and obesity, non-invasive imaging of islet cells, mechanisms of beta cell dysfunction in type 2 diabetes including beta cell gluco- and lipotoxicity, preservation or prevention of further loss of beta cell functional mass in individuals with impaired glucose tolerance and type 2 diabetes, genetic defects that elucidate beta cell dysfunction in type 2 diabetes, mechanisms of glucose dependent insulin and glucagon secretion, incretin regulation of hepatic glucose production, non-glucose actions of incretins, novel gut peptides implicated in metabolism and changes in physiology related to gastric bypass.

Funding Commitment and Instruments

This partnership Programme was established in 2008 for a total commitment of Euro 2.7 million to be distributed in the form of grants, each of up to Euro 300,000. In 2009 this amount was increased to Euro 400,000 each.

Awards in 2010

Based on the recommendations of the Review Committee, no awards were made.
Partnership for Diabetes Research in Europe

**Background**

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Headquartered in Denmark, Novo Nordisk has companies and information offices in more than 81 countries.

**Plan**

This new Programme will accept applications from all fields of diabetes research, including both basic and clinical research.

**Funding Commitments and Instruments**

This Programme continues the longstanding EFSD/Novo Nordisk Partnership, with a combined total commitment amounting to Euro 8.8 million. Grants of up to Euro 100,000 for basic research projects and Euro 400,000 for clinical research projects will be made available each year.

**Awards in 2010**

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

- Luc Bouwens: Free University Brussels - Belgium
- Per-Ola Carlsson: Uppsala University - Sweden
- Malin Flodström-Tullberg: Karolinska Institute - Stockholm, Sweden
- Anthony Gavalas: Academy of Athens - Greece
- Jarna Hannukainen: Turku University - Finland
- Leif Jansson: Uppsala University - Sweden
- Josep Jimenez-Chillaron: Sant Joan de Deu Foundation - Barcelona, Spain
- Richard Leslie: Queen Mary University of London - UK
- Cedric Moro: Rangueil Hospital - Toulouse, France
- Tina Vilsbøll: Copenhagen University - Denmark
European Programme for Research into Cardiovascular Risk Reduction in Patients with Diabetes

**Background**

Pfizer is one of the world's leading healthcare companies, providing human and animal pharmaceuticals, as well as consumer products. As part of its commitment to the care of patients with diabetes, Pfizer is dedicated to supporting research that will help identify ways to reduce cardiovascular risk, further our understanding of optimal treatment options, and ultimately improve the lives of people with diabetes.

**Plan**

The key objective of this research partnership is to understand better what best impacts cardiovascular risk reduction in patients with diabetes. Research proposals should aim to evaluate the impact of any aspect of the following on CV risk reduction in diabetes: educational tools, programmes and strategies, risk assessment tools/screening and diagnostic procedures and clinical interventions. This Programme replaced the EFSD/Pfizer Resource Awards for European Diabetes Research.

**Funding Commitments and Instruments**

Since the establishment of this Partnership in 2004, a total of **Euro 1.8 million** has been made available. In the current programme, **Euro 1.2 million** has been allocated to fund research grants up to Euro 300,000 each.

**Awards in 2010**

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

- Magnus Jensen: Gentofte University Hospital - Denmark
- Claudia Menzaghi: IRCCS - San Giovanni Rotondo, Italy
European Research Programme in Micro- and Macrovascular Complications of Diabetes

Background

The sanofi-aventis Group is the world’s third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas, and produces several medicines to treat diabetes including insulin. Their commitment to diabetes medicine has been longstanding since 1923 and the involvement of Hoechst, a legacy company of sanofi-aventis.

Plan

The key objective of this research partnership is to understand better what best impacts cardiovascular risk reduction in patients with diabetes, aiming to evaluate the impact of any aspect of the following on CV risk reduction in diabetes: educational tools, programmes, strategies, risk assessment tools/screening and diagnostic procedures and clinical interventions.

Funding Commitment and Instruments

A total of Euro 1.2 million was committed to fund basic research projects up to Euro 100,000 and clinical research projects up to Euro 400,000. Since its creation in 2006, the EFSD/sanofi-aventis Partnership has made available a total of Euro 3.625 million.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Agostino Consoli: University of Chieti - Italy
Hans-Peter Hammes: University of Heidelberg - Germany
Berend Iseman: University of Heidelberg - Germany
Katia Karalis: Academy of Athens - Greece
Ulf Landmesser: University Hospital Zurich - Switzerland
John Pernow: Karolinska Institute - Stockholm, Sweden
Rafael Simó: University Vall d’Hebron - Barcelona, Spain
FELLOWSHIP

PROGRAMMES

2010
Albert Renold Fellowships

Supported by an unrestricted educational grant from Merck Sharp & Dohme (MSD)

Albert Renold Fellowships, each of up to Euro 7,000, enable young scientists to travel to and stay at other institutions in order to learn new techniques in basic or clinical diabetes research. The duration of the stay should not exceed three months.

Albert Renold Fellowships are available throughout the year, and a decision is usually made within three weeks of applying.

In 2010 the following Fellowships were awarded:

Ashok Ayyappa: travelled to Karolinska Institute – Stockholm, Sweden
Noël Barengo: travelled to National University of La Plata – Buenos Aires, Argentina
Huriya Beyan: travelled to University of Miami - USA
Liliane Chamas: travelled to World Health Organisation – Geneva, Switzerland
Maartje de Wit: travelled to Miami University - USA
Teresa Delgado: travelled to University of Pittsburgh - USA
Meri Hovsepyan: travelled to Uppsala University - Sweden
Gabriel Loni Ekali: travelled to University of Prague – Czech Republic
Ronald Ma: travelled to Southampton University - UK
Uriëll Malanda: travelled to Oxford University - UK
Laura McCulloch: travelled to University Hospital Leipzig - Germany
Ruth Meex: travelled to Monash University – Clayton, Australia
Bilkisu Mohammed Mubi: travelled to Manchester Royal Infirmary - UK
Mercé Obach Cortadellas: travelled to University of British Columbia – Vancouver, Canada
Stavrola Paschou: travelled to Blizard Institute of Cell and Molecular Science – London, UK
Zalan Péterfi: travelled to Keck School of Medicine – Los Angeles, USA
Maren Pflüger: travelled to VTT Technical Research Centre – Espoo, Finland
Piotr Pietrzak: travelled to Berlin University - Germany
Dorit Schleinitz: travelled to Karolinska Institute – Stockholm, Sweden
Harold Sourij: travelled to University of Oxford - UK
Mary Travers: travelled to Lund University – Malmö, Sweden
Lucia Valentinová: travelled to The Oxford Centre - UK
Nicolas Venteclef: travelled to Karolinska Institute – Stockholm, Sweden
Ulrike Weyer: travelled to Joslin Diabetes Center – Boston, USA
Johannes Mansfeld: travelled to University of Cincinatti – USA
Ines de Sousa Lima: travelled to Harvard Medical School – Boston, USA
Simona Georgiana Popa: travelled to University of Pisa - Italy
The objective of the EFSD/CDS/Lilly Research Fellowships is to encourage collaborative research in the field of diabetes. Applications for fellowships may be accepted from applicants from China for study in a recognised research institution in Europe or its associated countries. Details of the partner organisations may be found under “EFSD/CDS/Lilly Collaborative Research Programme”.

Two Fellowships of up to Euro 50,000 each are awarded annually. Application may be made by any paid-up member of EASD under the age of 38 years on the 1 January in the year of the Fellowship Award and with demonstrated ability in the field of diabetes research.

Total funding of **Euro 300,000** has been committed from 2008 – 2010 for this Fellowship Programme.

In 2010 the following Fellowships were awarded:

- Chengjun Sun: Fudan University - Shanghai *collaborating with*
- Carani Sanjeevi: Karolinska Institute – Stockholm, Sweden
- Mao Dandan: Shu Guang Hospital - Shanghai *collaborating with*
- Rory McCrimmon: University of Dundee - UK
Research Fellowships

The objective of the EFSD/Lilly Research Fellowships is to encourage innovative research in the fields of metabolism and complications of diabetes, and to promote excellence in medical education.

In 2009, the number of Fellowships available was increased from two to four, and this will also be the case in 2010. Each Fellowship Award is up to Euro 50,000. Application may be made by any paid-up member of EASD under the age of 38 years on the 1 January in the year of the Fellowship Award and with demonstrated ability in the field of diabetes research.

These Fellowships form part of the EFSD/Lilly European Diabetes Research Fund, further details of which may be found under “EFSD/Lilly Diabetes Research Programme”.

In 2010 the following Fellowships were awarded:

Stefan Amisten: University of Oxford - UK
Christian Andersson: Sahlgrenska University – Gothenburg, Sweden
Céline Cruciani-Guglielmacci: University Paris Diderot - France
Heidi de Wet: University of Oxford - UK
Victorine Douin: Rangueil Hospital - Toulouse, France
Gianpaolo Fadini: University of Padova – Italy
Melis Karaca: University of Geneva - Switzerland
Eckhard Lammert: Heinrich-Heine University - Düsseldorf, Germany
Joan-Marc Servitja: IDIBAPS - Barcelona, Spain
Barbara Ukropcova: Slovak Academy of Sciences - Bratislava, Slovakia
NEW PROGRAMMES

2011
European Diabetes Research Programme in Patient Education

supported by an educational research grant from AstraZeneca/BMS

Background

The Astrazeneca/Bristol-Myers Squibb diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treatment of type 2 diabetes.

Plan

This Programme will support research into the clinical and medical evaluation of patient-related outcomes in relation to the type 2 diabetes chronic condition and the benefits of its treatment and management and the potential impact of educational and disease management programmes, focusing on holistic approaches to patients with type 2 diabetes, patient engagement and better understanding of the complex physiological and behavioural aspects of the disease.

Funding Commitment and Instruments

A total of Euro 900,000 for research funding will be distributed over three years from 2011 – 2013 through the award of grants, each of up to Euro 100,000.

Awards in 2011

The deadline for applications is 10 January 2011, with an anticipated award date of April 2011.
Programme for the Study of the Role of the Kidney in Diabetes

**Background**

Janssen represents the pharmaceutical companies of Johnson and Johnson, one of the leading healthcare companies in the world. Janssen develops and markets innovative, high-quality pharmaceutical products and services aimed at improving quality of life for people with medical needs across the world, with metabolic diseases as a key area of scientific interest.

**Plan**

This Programme is intended to stimulate and accelerate European research aimed at understanding the role of the kidney in diabetes, with special emphasis on the role of the renal glucose threshold (RGT) as an underlying pathophysiologic mechanism in type 2 diabetes. Both basic and clinical research in this scientific area will be supported.

**Funding Commitment and Instruments**

A total of Euro 500,000 for research funding will be made available. Research will be supported through the award of grants, each of up to Euro 100,000 for basic research projects and Euro 200,000 for clinical research projects.

**Awards in 2011**

The deadline for applications is 25 February 2011, with an anticipated award date of May 2011.
Fellowships for Research on the Endocrine Pancreas

The objective of the EFSD/MSD Research Fellowships is to encourage innovative research focusing on the endocrine pancreas and to support talented young investigators engaged in diabetes research.

These postdoctoral Fellowships in the amount of Euro 50,000 will be awarded to individuals already holding a PhD, MD or equivalent degree. Application may be made by any paid-up member of EASD under the age of 38 years on 1 January 2011.

EFSD/MSD Fellows are expected to change their place and ideally country of work during the funding period in order to pursue their research project in a new academic environment. However, either the current home or proposed host institution must be based in Europe or an associated country.

Awards in 2011

The deadline for applications is 10 March 2011, with an anticipated award date of June 2011.
Review Committee Members

EFSD is most grateful to the following colleagues who served on the various review committees of the 2010 partnership programmes:

Stephanie Amiel
Angelo Avogaro
Henning Beck-Nielsen
Francesco Beguinot
Christian Berne
Angelika Bierhaus
Nils Billestrup
Jonathon Bodansky
Fatima Bosch
Miriam Cnop
Mark Cooper
Leszek Czupryniak
Stefano Del Prato
Micaela Diamant
Malin Flodström-Tullberg
Paola Fioretto
Allan Flyvbjerg
Ramon Gomis de Barbara
Peter Grant
Hans-Peter Hammes
Torben Hansen
Kristian Hanssens
Steven Kahn
Fredrik Karpe
Filip Knop
Anna Krook
Markku Laakso

Yannick Le Marchand-Brustel
Valeriya Lyssenko
Sten Madsbad
Pierre Maechler
Nils Møller
Claes-Goran Östenson
Arne Östman
Timo Otonkoski
John Petrie
Jacques Philippe
Thomas Pieber
Andrew Renehan
Michael Roden
Guy Rutter
Giorgio Sesti
James Shaw
Michele Solimena
Giatgen Spinas
Coen Stehouwer
Norbert Stefan
Cees Tack
Jean-François Tanti
Jeremy Tavare
Dietholm Tschöpe
Luc Van Gaal
Antonio Vidal-Puig
John Wilding
EXECUTIVE COMMITTEE and ADMINISTRATION

Executive Committee:

President: U Smith - Göteborg
Vice President: F Bosch - Barcelona
Vice President: A Boulton - Manchester
Honorary Secretary: M Stumvoll - Leipzig
Honorary Treasurer: G Spinas - Zürich
Editor in Chief - *Diabetologia*: E Gale - Bristol
Chairman PGESC: J Nolan - Dublin

Chairman - EFSD: P A Halban - Geneva
Scientific Board: S Amiel – London
F Beguinot - Naples
E Ferrannini - Pisa
J Ferrer - Barcelona
M Laakso – Kuopio
T Pieber - Graz

Executive Director: V Jörgens – Düsseldorf
Vice Director: M Grüsser - Düsseldorf
Co-ordinators: S Köhnen - Düsseldorf
K Sommer - Düsseldorf

The European Foundation for the Study of Diabetes (EFSD)
Rheindorfer Weg 3
40591 Düsseldorf, Germany

Tel: + 49 211 75 84 69-0    Fax: + 49 211 75 84 69-29

[www.EuropeanDiabetesFoundation.org](http://www.EuropeanDiabetesFoundation.org)

Email: Foundation@easd.org

Bank details
Europäische Stiftung für Diabetesforschung – EFSD
Commerz Bank
Königsallee 37
40300 Düsseldorf, Germany

Account / Konto: 600 2146 00    Code / BLZ: 300 800 00

SWIFT / BIC: DRES DE FF 300

IBAN: DE31 3008 0000 0600 2146 00

EFSD is registered as a non-profit Foundation in Düsseldorf, Germany under registration number: 15.2.1-St.767
and at the Inland Revenue in Düsseldorf, Germany under tax number: 106/5744/1547